Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns

Table 4

Median survival of patients with soft tissue sarcoma having different histologic subtypes.

	Progression-free survival (month)		Overall survival (month)
	Median	95% CI	Median	95% CI
FS	3.9	2.1–5.7	17.9	15.0–20.8
SS	5.7	2.9–8.5	—	—
UPS	5.4	0–13.5	13.5	5.7–21.3
LMS	6.1	0–13.3	—	—
Others	—	—	15.8	10.2–21.4
Total	5.4	4.1–6.8	17.9	11.2–24.6